Brain-derived neurotrophic factor and autism: maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) study / Lisa A. CROEN in Autism Research, 1-2 (April 2008)  

Public ISBD [article]  inAutism Research > 1-2 (April 2008) . - p.130-137 Titre : Brain-derived neurotrophic factor and autism: maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) study Type de document : Texte imprimé et/ou numérique Auteurs : Lisa A. CROEN, Auteur ; David J. HANSEN, Auteur ; Martin KHARRAZI, Auteur ; Bruce FIREMAN, Auteur ; Cathleen K. YOSHIDA, Auteur ; Robert YOLKEN, Auteur ; Daniel BRAUNSCHWEIG, Auteur ; Paula GOINES, Auteur ; Judy VAN DE WATER, Auteur ; Judith K. GRETHER, Auteur Année de publication : 2008 Article en page(s) : p.130-137 Langues : Anglais (eng) Mots-clés : biologic-markers neurotrophin autism BDNF prenatal Index. décimale : PER Périodiques Résumé : To investigate levels of brain-derived neurotrophic factor (BDNF) in mid-pregnancy and neonatal blood specimens as early biologic markers for autism, we conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, CA. Cases (n=84) were all children receiving services for autism at the Regional Center of Orange County. Two comparison groups from the same study population were included: children with mental retardation or developmental delay (n=49) receiving services at the same regional center, and children not receiving services for developmental disabilities, randomly sampled from the California birth certificate files (n=159), and frequency matched to autism cases on sex, birth year, and birth month. BDNF concentrations were measured in archived mid-pregnancy and neonatal blood specimens drawn during routine prenatal and newborn screening using a highly sensitive bead-based assay (Luminex, Biosource Human BDNF Antibody Bead Kit, Invitrogen-Biosource, Carlsbad, CA). The concentration of BDNF in maternal mid-pregnancy and neonatal specimens was similar across all three study groups. These data do not support previous findings of an association between BDNF and autism and suggest that the concentration of BDNF during critical periods of early neurodevelopment is not likely to be a useful biomarker for autism susceptibility. En ligne : http://dx.doi.org/10.1002/aur.14 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=930 [article] Brain-derived neurotrophic factor and autism: maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) study [Texte imprimé et/ou numérique] / Lisa A. CROEN, Auteur ; David J. HANSEN, Auteur ; Martin KHARRAZI, Auteur ; Bruce FIREMAN, Auteur ; Cathleen K. YOSHIDA, Auteur ; Robert YOLKEN, Auteur ; Daniel BRAUNSCHWEIG, Auteur ; Paula GOINES, Auteur ; Judy VAN DE WATER, Auteur ; Judith K. GRETHER, Auteur . - 2008 . - p.130-137. Langues : Anglais (eng) in Autism Research > 1-2 (April 2008) . - p.130-137 Mots-clés : biologic-markers neurotrophin autism BDNF prenatal Index. décimale : PER Périodiques Résumé : To investigate levels of brain-derived neurotrophic factor (BDNF) in mid-pregnancy and neonatal blood specimens as early biologic markers for autism, we conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, CA. Cases (n=84) were all children receiving services for autism at the Regional Center of Orange County. Two comparison groups from the same study population were included: children with mental retardation or developmental delay (n=49) receiving services at the same regional center, and children not receiving services for developmental disabilities, randomly sampled from the California birth certificate files (n=159), and frequency matched to autism cases on sex, birth year, and birth month. BDNF concentrations were measured in archived mid-pregnancy and neonatal blood specimens drawn during routine prenatal and newborn screening using a highly sensitive bead-based assay (Luminex, Biosource Human BDNF Antibody Bead Kit, Invitrogen-Biosource, Carlsbad, CA). The concentration of BDNF in maternal mid-pregnancy and neonatal specimens was similar across all three study groups. These data do not support previous findings of an association between BDNF and autism and suggest that the concentration of BDNF during critical periods of early neurodevelopment is not likely to be a useful biomarker for autism susceptibility. En ligne : http://dx.doi.org/10.1002/aur.14 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=930

Neonatally measured immunoglobulins and risk of autism / Judith K. GRETHER in Autism Research, 3-6 (December 2010)  

Public ISBD [article]  inAutism Research > 3-6 (December 2010) . - p.323-332 Titre : Neonatally measured immunoglobulins and risk of autism Type de document : Texte imprimé et/ou numérique Auteurs : Judith K. GRETHER, Auteur ; Lisa A. CROEN, Auteur ; Meredith C. ANDERSON, Auteur ; Karin B. NELSON, Auteur ; Robert YOLKEN, Auteur Année de publication : 2010 Article en page(s) : p.323-332 Langues : Anglais (eng) Mots-clés : autism  ASD  maternal immune function  immunoglobulins and pregnancy Index. décimale : PER Périodiques Résumé : Previous studies indicate that prenatal exposure to infections is a possible pathway through which autism spectrum disorders (ASD) could be initiated. We investigated whether immunoglobulin levels in archived specimens obtained from newborns subsequently diagnosed with ASD are different from levels in newborn specimens from controls. Children with ASD born in six California counties in 1994 were ascertained through records of the California Department of Developmental Services (DDS) and Kaiser Permanente; controls were randomly selected using birth certificates. Archived newborn blood specimens were obtained from the California Genetic Disease Screening Program (GDSP) for N = 213 cases and N = 265 controls and assayed to determine levels of total IgG, antigen-specific IgG to selected common pathogens, total IgM, total IgA, and C-reactive protein (CRP). We did not find measurable levels of total IgM or IgA in any neonate and measurable CRP was present in only a few. No antigen-specific IgG antibodies were elevated in cases compared to controls and total IgG levels were lower. In adjusted models, a 10-unit increase in total IgG yielded an OR = 0.72 (95% CI 0.56, 0.91); a significantly decreasing trend in risk of ASD was observed across increasing exposure quartiles of total IgG (P = 0.01). The finding of lower IgG in cases may indicate maternal immune dysfunction during gestation and/or impaired transplacental transfer of immunoglobulins. Further investigation of IgG levels in newborns and the mechanisms by which they might be associated with ASD are warranted. En ligne : http://dx.doi.org/10.1002/aur.160 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=115 [article] Neonatally measured immunoglobulins and risk of autism [Texte imprimé et/ou numérique] / Judith K. GRETHER, Auteur ; Lisa A. CROEN, Auteur ; Meredith C. ANDERSON, Auteur ; Karin B. NELSON, Auteur ; Robert YOLKEN, Auteur . - 2010 . - p.323-332. Langues : Anglais (eng) in Autism Research > 3-6 (December 2010) . - p.323-332 Mots-clés : autism  ASD  maternal immune function  immunoglobulins and pregnancy Index. décimale : PER Périodiques Résumé : Previous studies indicate that prenatal exposure to infections is a possible pathway through which autism spectrum disorders (ASD) could be initiated. We investigated whether immunoglobulin levels in archived specimens obtained from newborns subsequently diagnosed with ASD are different from levels in newborn specimens from controls. Children with ASD born in six California counties in 1994 were ascertained through records of the California Department of Developmental Services (DDS) and Kaiser Permanente; controls were randomly selected using birth certificates. Archived newborn blood specimens were obtained from the California Genetic Disease Screening Program (GDSP) for N = 213 cases and N = 265 controls and assayed to determine levels of total IgG, antigen-specific IgG to selected common pathogens, total IgM, total IgA, and C-reactive protein (CRP). We did not find measurable levels of total IgM or IgA in any neonate and measurable CRP was present in only a few. No antigen-specific IgG antibodies were elevated in cases compared to controls and total IgG levels were lower. In adjusted models, a 10-unit increase in total IgG yielded an OR = 0.72 (95% CI 0.56, 0.91); a significantly decreasing trend in risk of ASD was observed across increasing exposure quartiles of total IgG (P = 0.01). The finding of lower IgG in cases may indicate maternal immune dysfunction during gestation and/or impaired transplacental transfer of immunoglobulins. Further investigation of IgG levels in newborns and the mechanisms by which they might be associated with ASD are warranted. En ligne : http://dx.doi.org/10.1002/aur.160 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=115

---

1 (1 - 2 / 2)